Ezetimibe phenoxy glucuronide-d₄  (Synonyms: Ezetimibe glucuronide-d₄; Ezetimibe β-D-glucuronide-d₄)

Ezetimibe phenoxy glucuronide-d₄ is the deuterium labeled Ezetimibe phenoxy glucuronide. Ezetimibe phenoxy glucuronide is the active metabolite of Ezetimibe. Antihyperlipoproteinemic activity[1]. Ezetimibe is a potent cholesterol absorption inhibitor[2].

After oral administration, Ezetimibe is absorbed in the small intestine and more than 80% of Ezetimibe metabolized to Ezetimibe Glucuronide^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

589.57

C₃₀H₂₅D₄F₂NO₉

1426174-41-5

190448-57-8

Solid

White to off-white

O[C@H]([C@H]([C@@H]([C@@H](C(O)=O)O1)O)O)[C@@H]1OC2=CC=C([C@H]([C@H]3CC[C@@H](C4=CC=C(F)C=C4)O)N(C5=C([2H])C([2H])=C(F)C([2H])=C5[2H])C3=O)C=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Stolk MF, et al. Severe hepatic side effects of ezetimibe. Clin Gastroenterol Hepatol. 2006 Jul;4(7):908-11.  [Content Brief]

  [2]. Lee DH, et al. Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. Free Radic Biol Med. 2016 Sep 12;99:520-532.  [Content Brief]